Fecal Calprotectin testing is **COVERED** for use in: (1) differentiating inflammatory bowel disease (e.g., Crohn’s disease, ulcerative colitis) from irritable bowel syndrome in individuals with symptoms that have lasted greater than four weeks, or (2) monitoring/managing disease activity in inflammatory bowel disease.

Fecal calprotectin testing is investigative and unproven, and therefore **NOT COVERED** for all other indications. There is insufficient reliable evidence in the form of high quality peer-reviewed medical literature to establish the effects on health care outcomes.

See also related Medica Coverage Policy, *Serological Markers for Diagnosis and Management of Inflammatory Bowel Disease (IBD) or Irritable Bowel Syndrome (IBS)*.

**Description**
Fecal calprotectin testing is a laboratory test that measures the amount of calprotectin present in stool. Calprotectin is a 36-kDa zinc and calcium binding protein derived from neutrophils and released by immune system cells that is thought to trigger and maintain inflammation. Therefore, it has been proposed as a noninvasive method to differentiate between inflammatory and noninflammatory gastrointestinal conditions (e.g., irritable bowel disease [IBD], irritable bowel syndrome [IBS], Crohn disease), monitor response to therapy, and predict disease recurrence. Fecal calprotectin is also under investigation as a marker in colorectal cancer, transplant rejection, and a number of other gastrointestinal conditions.

**FDA Approval**
Use of fecal calprotectin to differentiate IBD from IBS and for monitoring disease, including Crohn disease, is considered a procedure and is, therefore, not subject to FDA regulation. However, any medical devices, drugs, biologics, or tests used as a part of this procedure may be subject to FDA regulation. Fecal calprotectin test systems are regulated as FDA class II devices. Multiple fecal calprotectin test devices have been granted FDA clearance.
Prior Authorization
Prior authorization is not applicable. Claims for this service are subject to retrospective review and denial of coverage, as investigative services are not eligible for reimbursement.

Coding Considerations
Use the current applicable CPT/HCPCS code(s). The following codes are included below for informational purposes only, and are subject to change without notice. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement.

CPT Codes
83993 – Calprotectin, fecal

Original Effective Date: 5/1/2011
Re-Review Date(s): 2/19/2014
2/15/2017
2/19/2020

© 2011-2020 Medica. Medica® is a registered service mark of Medica Health Plans. “Medica” refers to the family of health services companies that includes Medica Health Plans, Medica Community Health Plan, Medica Insurance Company, Medica Self-Insured, MMSI, Inc. d/b/a Medica Health Plan Solutions, Medica Health Management, LLC and the Medica Foundation.